

Improved
Glycemic
Control with
Proven Safety



In T2DM with High CV Risk and Uncontrolled
on Monotherapy

^{Rx} Diet, Exercise &

AffOodapa-S [®] $\frac{5}{50} / \frac{10}{100}$
Dapagliflozin 5/10 mg + Sitagliptin 50/100 mg Tablets



In T2DM with High CV Risk and Uncontrolled on Monotherapy

^{Rx} Diet, Exercise &

Affodapa-S [®] $\frac{5}{50} / \frac{10}{100}$
Dapagliflozin 5/10 mg + Sitagliptin 50/100 mg Tablets

Background

The prevalence of Type-2 Diabetes Mellitus (T2DM) is increasing worldwide, often leading to metabolic complications and higher cardiovascular (CV) risk. Since CV morbidity and mortality remain major concerns, early combination therapy targeting key defects in T2DM is considered a rational approach. Clinical evidence shows that SGLT-2 inhibitors and DPP-4 inhibitors reduce glycemic variability, and combining Dapagliflozin with Sitagliptin offers added clinical benefits with good tolerability in patients with uncontrolled T2DM.

Description

Affodapa-S is a fixed-dose combination of Dapagliflozin (5 mg / 10mg and Sitagliptin (50 mg / 100 mg), available in form tablets.

Indication

Affodapa-S is indicated as an adjunct to diet and exercise **In T2DM with High CV Risk and Uncontrolled on Monotherapy**

Mechanism of Action

- ✓ **Dapagliflozin** : Selectively inhibits SGLT-2 in the kidney, reduces glucose reabsorption, increases urinary glucose excretion, and thereby lower blood glucose levels. This mechanism also contributes to modest weight reduction and improved glycemic control.
- ✓ **Sitagliptin** : Enhances incretin activity (GLP-1 and GIP) by inhibiting their breakdown. This increases insulin secretion from pancreatic beta cells and decreases glucagon release from alpha cells, resulting in reduced hepatic glucose production and improved overall glycemic regulation.

Dosage and Administration

The recommended dose of Affodapa-S is one tablet daily, or as prescribed by the doctor.



Corp. & Regd. Office:

1009-1010, Chiranjiv Tower, 43, Nehru Place,
New Delhi - 110019 Tel.: 011-47589500-51 (50 lines)
Web: www.medicamen.com/lifesciences
E-mail: info@medicamenlifesciences.com

I am: _____
 Call me on: _____
 Mail me at: _____

2025 All rights reserved, Medicamen Lifesciences Pvt Ltd